Actinogen is advancing a revolutionary oral therapeutic, Xanamem^®, through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation.

Final, 246th participant randomized in XanaMIA AD trial – topline results Nov 2026

ACW has announced the enrolment and start of treatment for the final participant in the XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial. This means that topline, final results will be available in November 2026. Interim results are expected at the end of January 2026.

ACW is holding a live webinar & Q&A session 18 December 2025 at 11am Sydney time. Click HERE to register and join the live event, or to watch a replay after the event.

ACW CEO & CFO present at Bell Potter Healthcare conference

ACW CEO, Dr Steven Gourlay and CFO, Mr Will Souter, presented at the Bell Potter Healthcare Conference 2025

ACW 2025 AGM - Chair's address & CEO's presentation

Actinogen has released the Chair’s address and CEO’s slide presentation for its 2025 Annual General Meeting held 19 November 2025.

Click here to view AGM voting results

Actinogen receives positive recommendation from first Data Monitoring Committee Meeting to continue Alzheimer's phase 2b/3 trial without amendment.

ACW is pleased to announce the positive outcome of the first meeting of its XanaMIA phase 2b/3 trial’s independent Data Monitoring Committee (DMC) to continue the trial without amendment.

ACW Progress Update and Q&A Webinar

ACW held a progress update and Q&A webinar on 28 October 2025. The leadership team, led by CEO, Dr Steven Gourlay outlined the company’s significant progress over recent months and discuss key upcoming milestones. 

A recording of the webinar is now available on Actinogen’s YouTube channel.

ACW September 2025 quarterly activity report & Appendix 4C

ACW has released its quarterly activity report and Appendix 4C cash flow report for the three-month period ended 30 September 2025.

The announcement on our InvestorHub includes a video summary from CEO Steven Gourlay.

ACW CEO presents at Canaccord/Wilsons Drug & Device conference

CEO, Dr Steven Gourlay, has presented at the Canaccord Drug & Device Conference in Noosa, Queensland

The three-day conference is a key opportunity for leading and emerging biotech, healthcare and lifescience companies to outline their investment value propositions to analysts and institutional investors.

Dr Gourlay’s presentation outlines the success to date of ACW’s clinical development program for its novel oral therapy Xanamem, upcoming milestones, and its large market potential driven by the high unmet need for a safe and effective oral drug in Alzheimer’s disease.